Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Jun;39(6):1086-99.
doi: 10.1016/j.jpainsymman.2010.02.006.

ASCPRO recommendations for the assessment of fatigue as an outcome in clinical trials

Affiliations
Review

ASCPRO recommendations for the assessment of fatigue as an outcome in clinical trials

Andrea M Barsevick et al. J Pain Symptom Manage. 2010 Jun.

Abstract

Context: Development of pharmacological and behavioral interventions for cancer-related fatigue (CRF) requires adequate measures of this symptom. A guidance document from the Food and Drug Administration offers criteria for the formulation and evaluation of patient-reported outcome measures used in clinical trials to support drug or device labeling claims.

Methods: An independent working group, ASCPRO (Assessing Symptoms of Cancer Using Patient-Reported Outcomes), has begun developing recommendations for the measurement of symptoms in oncology clinical trials. The recommendations of the Fatigue Task Force for measurement of CRF are presented here.

Results: There was consensus that CRF could be measured effectively in clinical trials as the sensation of fatigue or tiredness, impact of fatigue/tiredness on usual functioning, or as both sensation and impact. The ASCPRO Fatigue Task Force constructed a definition and conceptual model to guide the measurement of CRF. ASCPRO recommendations do not endorse a specific fatigue measure but clarify how to evaluate and implement fatigue assessments in clinical studies. The selection of a CRF measure should be tailored to the goals of the research. Measurement issues related to various research environments were also discussed.

Conclusions: There exist in the literature good measures of CRF for clinical trials, with strong evidence of clarity and comprehensibility to patients, content and construct validity, reliability, and sensitivity to change in conditions in which one would expect them to change (assay sensitivity), and sufficient evidence to establish guides for interpreting changes in scores. Direction for future research is discussed.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
ASCPRO Conceptual Model of Cancer-related Fatigue

Similar articles

Cited by

References

    1. Armes J. The experience of cancer-related fatigue. In: Armes J, Krishnasamy M, Higginson I, editors. Fatigue in cancer. Oxford University Press; Oxford: 2004. pp. 137–155.
    1. Higginson IJ, Armes J, Krishnasamy M. Introduction. In: Armes J, Krishnasamy M, Higginson I, editors. Fatigue in cancer. Oxford University Press; Oxford: 2004. pp. xvii–xxi.
    1. ASCPRO Assessing the symptoms of cancer using patient-reported outcomes. 2007. Available from: www.ASCPRO.org.
    1. US Department of Health and Human Services . Guidance for industry, patient-reported outcome measures: Use in medical product development to support labeling claims. US Food and Drug Administration; Rockville, MD: 2009. - PubMed
    1. OMERACT Outcome measures in rheumatology. 2010. Available from: www.q2q.co.uk/omeract10/